PMID- 24639403
OWN - NLM
STAT- MEDLINE
DCOM- 20150713
LR  - 20151119
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 30
IP  - 8
DP  - 2014 Nov
TI  - Switching to multiple daily injection therapy with glulisine improves glycaemic 
      control, vascular damage and treatment satisfaction in basal insulin 
      glargine-injected diabetic patients.
PG  - 693-700
LID - 10.1002/dmrr.2537 [doi]
AB  - BACKGROUND: Basal and bolus insulin therapy is required for strict blood control 
      in diabetic patients, which could lead to prevention of vascular complications in 
      diabetes. However, the optimal combination regimen is not well established. 
      METHODS: Fifty-nine diabetic patients (49 type 1 and 10 type 2; 52.9 +/- 13.3 years 
      old) whose blood glucose levels were uncontrolled (HbA1c  > 6.2%) by combination 
      treatment of basal insulin glargine with multiple daily pre-meal injections of 
      bolus short-acting insulin [aspart (n = 19), lispro (n = 37) and regular human 
      insulin (n = 3)] for at least 8 weeks were enrolled in this study. We examined 
      whether glycaemic control and vascular injury were improved by replacement of 
      short-acting insulin with glulisine. Patient satisfaction was assessed with 
      Diabetes Treatment Satisfaction Questionnaire. RESULTS: Although bolus and basal 
      insulin doses were almost unchanged before and after replacement therapy, 
      switching to glulisine insulin for 24 weeks significantly decreased level of 
      HbA1c , advanced glycation end products (AGEs), soluble receptor for AGEs 
      (sRAGE), monocyte chemoattractant protein-1 (MCP-1) and urinary albumin 
      excretion. In multiple stepwise regression analysis, change in MCP-1 values from 
      baseline (DeltaMCP-1) was a sole determinant of log urinary albumin excretion. DeltaAGEs 
      and DeltasRAGE were independently correlated with each other. The relationship 
      between DeltaMCP-1 and DeltasRAGE was marginally significant (p = 0.05). Replacement of 
      short-acting insulin by glulisine significantly increased Diabetes Treatment 
      Satisfaction Questionnaire scores. CONCLUSIONS: Our present study suggests that 
      combination therapy of glargine with multiple daily pre-meal injections of 
      glulisine might show superior efficacy in controlling blood glucose, preventing 
      vascular damage and improving treatment satisfaction in diabetic patients.
CI  - Copyright (c) 2014 John Wiley & Sons, Ltd.
FAU - Yanagisawa, Katsuyuki
AU  - Yanagisawa K
AD  - Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, 
      Japan.
FAU - Ashihara, Junya
AU  - Ashihara J
FAU - Obara, Shinji
AU  - Obara S
FAU - Wada, Norio
AU  - Wada N
FAU - Takeuchi, Masayoshi
AU  - Takeuchi M
FAU - Nishino, Yuri
AU  - Nishino Y
FAU - Maeda, Sayaka
AU  - Maeda S
FAU - Ishibashi, Yuji
AU  - Ishibashi Y
FAU - Yamagishi, Sho-ichi
AU  - Yamagishi S
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Biomarkers)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin, Long-Acting)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 7XIY785AZD (insulin glulisine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood/urine
MH  - Diabetes Mellitus, Type 1/blood/complications/*drug therapy/urine
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy/urine
MH  - Diabetic Angiopathies/*prevention & control
MH  - Drug Administration Schedule
MH  - Drug Resistance
MH  - Drug Therapy, Combination/adverse effects
MH  - Female
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemia/chemically induced/prevention & control
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects/therapeutic use
MH  - Injections, Subcutaneous
MH  - Insulin/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Insulin Glargine
MH  - Insulin, Long-Acting/administration & dosage/adverse effects/therapeutic use
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - *Patient Satisfaction
OTO - NOTNLM
OT  - RAGE
OT  - glycation
OT  - oxidative damage
EDAT- 2014/03/19 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/03/19 06:00
PHST- 2013/12/12 00:00 [received]
PHST- 2014/02/04 00:00 [revised]
PHST- 2014/02/04 00:00 [accepted]
PHST- 2014/03/19 06:00 [entrez]
PHST- 2014/03/19 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.1002/dmrr.2537 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2014 Nov;30(8):693-700. doi: 10.1002/dmrr.2537.